Mycobacterial characteristics and treatment outcomes in mycobacterium abscessus lung disease

Clinical Infectious Diseases

Volumn 64, Issue 3, 2017, Pages 309-316

  Koh, Won Jung ^a   Jeong, Byeong Ho ^a   Kim, Su Young ^a   Jeon, Kyeongman ^a   Park, Kyoung Un ^b   Jhun, Byung Woo ^a   Lee, Hyun ^a   Park, Hye Yun ^a   Kim, Dae Hun ^a   Huh, Hee Jae ^c   Ki, Chang Seok ^c   Lee, Nam Yong ^c   Kim, Hong Kwan ^a   Choi, Yong Soo ^a   Kim, Jhingook ^a   Lee, Seung Heon ^d   Kim, Chang Ki ^d   Shin, Sung Jae ^e   Daley, Charles L ^f   Kim, Hojoong ^a   Kwon, O Jung ^a   more..

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Department of Laboratory Medicine and Genetics ^*  (South Korea)

^d Korean Institute of Tuberculosis   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f DEPARTMENT OF MEDICINE   (United States)

Author keywords

Lung disease; Macrolides; Mycobacterium abscessus; Nontuberculous mycobacteria

Indexed keywords

AMIKACIN; AZITHROMYCIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; IMIPENEM; MOXIFLOXACIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; FEMALE; GENETIC ANALYSIS; GENOTYPE; HUMAN; LEUKOPENIA; LUNG DISEASE; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MORPHOTYPE; MYCOBACTERIUM ABSCESSUS; PREMEDICATION; PRIORITY JOURNAL; RECURRENT DISEASE; SPUTUM; TREATMENT DURATION; TREATMENT OUTCOME; AGED; ANTIBIOTIC RESISTANCE; ATYPICAL MYCOBACTERIUM; CLASSIFICATION; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; LUNG DISEASES; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; RETROSPECTIVE STUDY;

AGED; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; FEMALE; GENOTYPE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; RECURRENCE; RETROSPECTIVE STUDIES; SPUTUM; TREATMENT OUTCOME;

EID: 85019678204     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw724     Document Type: Article

References (40)

1. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: A review. Clin Chest Med 2015; 36:13-34.
2. Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis 2016; 45:123-34.
3. Griffith DE, Aksamit T, Brown-Elliott BA, et al; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Diseases Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367-416.
4. Floto RA, Olivier KN, Saiman L, et al; US Cystic Fibrosis Foundation and European Cystic Fibrosis Society. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016; 71 Suppl 1:i1-22.
5. Koh WJ, Stout JE, Yew WW. Advances in the management of pulmonary disease due to Mycobacterium abscessus complex. Int J Tuberc Lung Dis 2014; 18:1141-8.
6. Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011; 183:405-10.
7. Lyu J, Kim BJ, Kim BJ, et al. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease. Respir Med 2014; 108:1706-12.
8. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm, confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53:1367-76.
9. Bastian S, Veziris N, Roux AL, et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm and rrl sequencing. Antimicrob Agents Chemother 2011; 55:775-81.
10. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Update 2012; 15:149-61.
11. Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: A retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009; 180:896-902.
12. Koh WJ, Jeong BH, Jeon K, et al. Oral macrolide therapy following short-term combination antibiotic treatment for Mycobacterium massiliense lung disease. Chest 2016; 150:1211-21.
13. Kim HS, Lee KS, Koh WJ, et al. Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy. Radiology 2012; 263:260-70.
14. Koh WJ, Kwon OJ, Jeon K, et al. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006; 129:341-8.
15. Wang HY, Bang H, Kim S, Koh WJ, Lee H. Identification of Mycobacterium species in direct respiratory specimens using reverse blot hybridisation assay. Int J Tuberc Lung Dis 2014; 18:1114-20.
16. Kim SY, Shin SJ, Jeong BH, Koh WJ. Successful antibiotic treatment of pulmonary disease caused by Mycobacterium abscessus subsp. abscessus with C-to-T mutation at position 19 in erm gene: case report. BMC Infect Dis 2016; 16:207.
17. Clinical Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard. 2nd ed. CLSI document No. M24-A2. Wayne, PA: Clinical Laboratory Standards Institute, 2011.
18. Healy M, Huong J, Bittner T, et al. Microbial DNA typing by automated repetitive-sequence-based PCR. J Clin Microbiol 2005; 43:199-207.
19. Mougari F, Raskine L, Ferroni A, et al. Clonal relationship and differentiation among Mycobacterium abscessus isolates as determined using the semiautomated repetitive extragenic palindromic sequence PCR-based DiversiLab system. J Clin Microbiol 2014; 52:1969-77.
20. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011; 52:565-71.
21. Lyu J, Jang HJ, Song JW, et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir Med 2011; 105:781-7.
22. Howard ST, Rhoades E, Recht J, et al. Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype. Microbiology 2006; 152(Pt 6):1581-90.
23. Caverly LJ, Caceres SM, Fratelli C, et al. Mycobacterium abscessus morphotype comparison in a murine model. PLoS One 2015; 10:e0117657.
24. Sanguinetti M, Ardito F, Fiscarelli E, et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 2001; 39:816-9.
25. Catherinot E, Roux AL, Macheras E, et al. Acute respiratory failure involving an R variant of Mycobacterium abscessus. J Clin Microbiol 2009; 47:271-4.
26. Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012; 186:917-25.
27. Yoshida S, Tsuyuguchi K, Suzuki K, et al. Further isolation of Mycobacterium abscessus subsp. abscessus and subsp. bolletii in different regions of Japan and susceptibility of these isolates to antimicrobial agents. Int J Antimicrob Agents 2013; 42:226-31.
28. Lee SH, Yoo HK, Kim SH, et al. The drug resistance profile of Mycobacterium abscessus group strains from Korea. Ann Lab Med 2014; 34:31-7.
29. Brown-Elliott BA, Vasireddy S, Vasireddy R, et al. Utility of sequencing the erm gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs. J Clin Microbiol 2015; 53:1211-5.
30. Shallom SJ, Moura NS, Olivier KN, Sampaio EP, Holland SM, Zelazny AM. New real-time PCR assays for detection of inducible and acquired clarithromycin resistance in the Mycobacterium abscessus group. J Clin Microbiol 2015; 53:3430-7.
31. Mougari F, Amarsy R, Veziris N, et al. Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar. J Antimicrob Chemother 2016; 71:2208-12.
32. Maurer FP, Ruegger V, Ritter C, Bloemberg GV, Bottger EC. Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm. J Antimicrob Chemother 2012; 67:2606-11.
33. Wallace RJ Jr, Zhang Y, Brown BA, et al. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med 1998; 158:1235-44.
34. Wallace Jr RJ, Zhang Y, Brown-Elliott BA, et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis 2002; 186:266-73.
35. Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: A retrospective cohort study. Lancet 2013; 381:1551-60.
36. Lee BY, Kim S, Hong Y, et al. Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease. Antimicrob Agents Chemother 2015; 59:2972-7.
37. Boyle DP, Zembower TR, Reddy S, Qi C. Comparison of clinical features, virulence, and relapse among Mycobacterium avium complex species. Am J Respir Crit Care Med 2015; 191:1310-7.
38. Wallace RJ Jr, Brown-Elliott BA, McNulty S, et al. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest 2014; 146:276-82.
39. Jarand J, Davis JP, Cowie RL, Field SK, Fisher DA. Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or rifampin. Chest 2016; 149:1285-93.
40. Griffith DE, Philley JV, Brown-Elliott BA, et al. The significance of Mycobacterium abscessus subspecies abscessus isolation during Mycobacterium avium complex lung disease therapy. Chest 2015; 147:1369-75.